Back To The Future: Waxman Biosimilars Bill Offers New-Drug Style Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
With five years of market protection, but an extra year possible for an additional indication, the Commerce Committee chairman hopes to father another abbreviated industry.